🇺🇸

Index Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — May 11, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (May 11, 2026 period), mixed sentiment dominates with 70% of operating companies (e.g., NESR, Kodiak, B&W) reporting YoY revenue growth averaging +25% in Q1 2026, driven by energy/services and acquisitions, but profitability challenged by one-time costs, margin compression (avg -50bps in 8/15 reporters), and rising provisions (e.g., Western Alliance +583% YoY). Capital allocation trends positive with new dividends (NESR $0.10/share Q4 2026 start, ARKO $2.00 annual), buybacks ($50M NESR, $57M Prosperity), and debt reductions (ARKO -50% QoQ, B&W net debt $42.4M). Forward guidance largely raised/affirmed (Kodiak EBITDA $820-860M, eXp FY rev $4.85-5.15B), signaling resilience amid M&A activity (Sonida $1.8B CHP, Olaplex $1.4B Henkel). Institutional 13Fs (11 filings) show heavy tech concentration (Apple, NVDA, MSFT top holdings across $20B+ AUM), indicating conviction in mega-caps. Key themes: energy rebound, banking consolidation, biotech catalysts; actionable now: buy growth outliers pre-earnings, monitor merger risks.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 11, 2026

Across 50 filings from S&P 500 Consumer Discretionary and related sectors, Q1 2026 results show mixed revenue trends with 6/12 quarterly reporters posting YoY declines averaging -19% (e.g., OPAL Fuels -14%, bioAffinity -27%, Bitfarms -22%), offset by outperformers like Village Farms +27% sales and Target Hospitality +4% revenue, amid widespread margin compression and net losses in 7/12 cases. Leadership transitions dominate positive narratives (Faraday Future founder CEO return, SolarEdge CFO appoint, Atmus SVP), signaling strategic resets, while M&A activity surges with Dream Finders' Beazer bid, Flag Ship LOI, and Odyssey merger risks. Capital allocation leans supportive with FS KKR's $150M tender/$300M buyback, Village Farms $6.4M repurchases, and Ellington $0.13 monthly dividend, but cash burns and going concern doubts (Perma-Fix, bioAffinity) flag liquidity strains. Institutional 13Fs (13/50 filings) reveal stable mega-cap tech overweight (Apple, Alphabet top across MUFG, Knights of Columbus, etc.), implying conviction in consumer tech proxies. Forward guidance mixed but intact (Target $370-380M FY rev, OPAL maintains FY), building a catalyst-rich calendar amid EV/robotics growth (Faraday 68 robots shipped, +gross margins). Portfolio implication: Selective opportunities in turnarounds with contracts/guidance, avoid high-burn losers; sector faces utilization drops (Target beds 54% vs 60%) but AI/infra tailwinds emerging.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 11, 2026

Across 50 filings in the S&P 500 Healthcare stream, 13F-HR reports dominate (over 60%), revealing institutional portfolios overwhelmingly tilted to tech megacaps (Apple, MSFT, NVDA topping 25+ filers, e.g., $709M Apple in Cincinnati Financial) with secondary but stable healthcare exposure (AbbVie $270B Citigroup, $305M Cincinnati Insurance, Lilly $7M CIGNA). Healthcare-specific filings highlight biotech momentum with positive clinical data (Inhibrx Phase 2 ORR 44% vs 21% control +24% edge, MBX Biosciences 7% weight loss Phase 1) contrasting small-cap deterioration (Elicio Q1 loss widened to $11.8M +5% YoY, BioScience rev -38.8% YoY to $0.75M). Adjacent financials show resilient NII growth averaging +12% YoY (Esquire +23%, C&F +11%, Flushing swing to $5.8M profit) amid rising provisions (+20-100%). Capital allocation leans shareholder-friendly (Ellington monthly $0.13 dividend June 30, News Corp $1B buyback ongoing, Flushing dividend doubled to $0.44), but dilution risks loom (ACRES ~105% share issuance vote). Forward catalysts cluster Q3-Q4 2026 (Inhibrx Phase 3/PFS, MBX 12-wk data); neutral-to-mixed sentiment prevails with no notable insider trading patterns. Portfolio implication: tactical biotech alpha amid broad market tech rotation, monitor dilution votes.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 08, 2026

Across 38 filings dominated by financials/banks (despite tech stream focus), Q1 2026 showed resilient net interest income growth averaging +14% YoY in 9 banks (e.g., CWBC +11.9%, Muncy +18.6%, CTBI +15%), offset by rising expenses (+6-15% YoY) and comprehensive income declines from unrealized securities losses (e.g., CBU -44% YoY). Tech highlights include Fortinet's standout +20.1% YoY revenue (+40.5% products) and +23.3% net income, with $823M buybacks signaling conviction, while NVIDIA added a director (neutral). Institutional 13Fs (8 filings) reveal heavy tech exposure (AAPL top in 4/8, MSFT/AVGO/CSCO prominent), portfolio values $1B-$13B. Mixed sentiments prevail (26/38), with REITs/ETFs facing NOI/NAV declines (CMCT -9% rev, Palladium -23.8% net assets QoQ). Capital allocation leans shareholder-friendly (buybacks, dividends flat/up), but risks like delistings (Aditxt, Scinai) and going concerns (AParadise) loom. Forward catalysts include mergers (UCB Q3 close), Nasdaq deadlines (Scinai Sep 8), and spin-offs (MSGS exploring).

21 high priority 17 medium 38 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 08, 2026

Across 41 filings from NASDAQ-100 related entities (primarily smaller financials, industrials, and commodities despite focus), Q1 2026 results show resilient net income growth in 8/10 regional banks averaging +25% YoY (e.g., Community West +38.5%, Muncy +64.7%, CTBI +24%) driven by NII expansion (+12-18% YoY), offset by comprehensive income declines from unrealized securities losses averaging -20-30%. Commodity plays like Alpha Metallurgical Resources (AMR) improved Q1 losses to $11M from $34M YoY with Adjusted EBITDA +5% QoQ and 2026 guidance for 14.4-15.4M met tons at $95-101/ton costs, while precious metals ETFs diverged (GLTR assets +12.7% QoQ but returns -67% YoY; Palladium -23.8% QoQ). Sports/media firms like MSG reported +2% revenue but -94% operating income YoY due to expense inflation (+12%), and annual meetings (PEP, Camden) passed positively with strong director support. Capital allocation leans shareholder-friendly with buybacks (AMR $23M Q1 vs $5M YoY) and steady dividends, but M&A/integration risks loom (Radian Inigo acquisition, UCB-Peach merger Q3 close). Overall mixed sentiment (24/41 filings) signals sector rotation opportunities in banks/commodities amid metals weakness, with no major insider activity but positive settlements (ImmuCell +$2M) and financings (AIM $4.2M warrants).

22 high priority 19 medium 41 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 08, 2026

Across 50 SEC filings from the USA S&P 500 Financials intelligence stream (primarily REITs, BDCs, and select financial services amid broader sector crossovers), mixed sentiment dominates (28/50 filings), reflecting robust revenue growth averaging +18% YoY in Q1 2026 reporters (e.g., Astrana Health +56%, Cloudflare +33.5%, Monster Beverage +26.9%) offset by margin compression (-100 to -200 bps avg in 12 cos) and widened operating losses from opex inflation (e.g., R&D +31% Cloudflare, SG&A +22.9% Natera). Capital allocation prioritizes returns with 15+ instances of dividends (e.g., Strawberry Fields $0.17/share June 30 record, Kodiak $0.49/share May 28), buybacks ($1B News Corp, $200M Itron, $75M new Innospec), and repurchases (Yum China $218M Q1). Forward-looking catalysts include guidance upgrades (Playtika rev $2.75-2.85B FY26, W.W. Grainger EPS $44.25-46.25, OSS rev +20-25%), M&A progress (Gold Resource merger Q3 close, Gran Tierra FCF $95-115M), and financings ($35M Cellectar, $53M net Comstock). REITs face vacancy risks (NewLake 3 properties vacant) but maintain liquidity (1.6% debt/gross assets); BDCs like Goldman Sachs show stable yields (11%) despite NAV -3.7%. Portfolio-level: Growth reacceleration post-cost pressures, with alpha in cap alloc leaders; monitor Q2 dividends, earnings calls for guidance confirmation.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 08, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples stream (broadly encompassing food/beverages, household/personal care, with some adjacent exposure), Q1 2026 results reveal robust revenue growth in outperformers like Monster Beverage (+26.9% YoY to $2.35B) and Cloudflare (+33.5% YoY to $640M), but widespread margin pressures and mixed profitability with 12/25 10-Q filers showing operating losses or compressions averaging -150bps YoY amid rising OpEx (e.g., Cloudflare +24.2%, Topgolf +15% gross profit but cash burn). Dividend declarations remain steady across 5 filers (e.g., STRW $0.17, Kodiak $0.49), signaling shareholder focus, while capital returns via buybacks surged (Monster $134M vs $17M YoY, Consensus $17M). M&A activity highlights TDS's non-binding proposal for Array (all-stock, adding fiber addresses), and forward guidance largely unchanged or raised (PLAINS EBITDA midpoint +$130M to $2.88B). Institutional 13Fs (11 filers) show neutral positioning with tech-heavy holdings stable, no major shifts. Portfolio-level trend: 8/15 revenue reporters >10% YoY growth, but cash flows volatile (9 declining QoQ); implications favor resilient growers like Monster amid cost headwinds, watch dividend payers for yield stability.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 08, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including aerospace, distributors, services, and cross-sector peers), Q1 2026 results reveal resilient revenue growth averaging +15% YoY in 12/18 reporting companies (e.g., Grainger +10.1%, Monster +26.9%, ANI +20.5%, Republic +2.6%), but mixed profitability with 7/18 showing losses or widened deficits (Ducommun swing to -$37M, Saga op loss +42%, Calumet -$317M). Margin trends diverge: expansions in Grainger (+110 bps to 16.7%) and Monster (+operating), compressions elsewhere (ANI GAAP gross -320 bps). Capital allocation emphasizes returns with accelerated buybacks (Republic $317M vs $55M prior, Monster $134M vs $17M, S&T $50M) and dividend hikes (Grainger +10%, Red River $0.25 vs $0.12). Forward-looking catalysts include raised FY26 guidance (Grainger sales $19.2-19.6B/EPS $44.25-46.25, ANI rev $1.08-1.14B), Enbridge reaffirm EBITDA C$20.2-20.8B, and M&A/IPOs (Applied Aerospace S-1 NYSE:AADX, TDS Array acquisition proposal). Institutional 13Fs highlight tech/AI overweight (e.g., Mystic top Apple/MSFT/NVDA, Central Asset semis), signaling conviction outside core industrials. Portfolio-level: Industrials show organic strength amid capex moderation, but litigation/outages pose risks; banks average +20% income growth but rising provisions signal credit watch.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 08, 2026

Across 16 filings in the USA S&P 500 Energy intelligence stream (with contextual inclusions), dominant themes include strong shareholder approvals at annual meetings for energy peers like Chesapeake Utilities (all proposals passed with 83-98% support), Valero Energy (92-99% approvals), and others, signaling governance stability amid sector volatility. Period-over-period trends reveal mixed financial health: robust YoY net income growth in financial-adjacent firms (Peapack-Gladstone +86% to $14.2M, John Marshall +27% to $6.1M) contrasts with declines in others (Token Cat revenues -70% YoY to RMB49M then -36%, Copper Property net income -29% to $11.5M, distributions -48% to $0.26/share). Energy-specific highlights feature ExxonMobil's defense of performance-tied CEO comp (81% in long-vest shares, TDC down YoY on lower earnings) and Valero's smooth exec transition; deal activity shines with Xometry's $50M Siemens private placement. 13F-HR filings (Marshall, Hestia, Seneschal, Japan Post, Mathes) provide neutral institutional snapshots with indirect energy exposure (e.g., Mathes top holding GE Vernova $15.2M). Capital allocation shows distribution cuts (Copper) vs stability elsewhere; no major insider trades noted but proxy comp votes affirm alignment. Overall, positive meeting outcomes bolster near-term sentiment, but deteriorating metrics in select names flag caution in a high-materiality (avg 6.5/10) set, with catalysts like Hooker's June 9 AGM offering alpha potential.

7 high priority 9 medium 16 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 08, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (Q1 2026 focus), overarching themes reveal mixed corporate performance with 14/25 quarterly reporters showing YoY revenue growth averaging +25% in outperformers like Monster Beverage (+26.9%), Vistra (+43%), CoreWeave (+111.6%), and AMN Healthcare (+100%), contrasted by declines averaging -6% in laggards like Saga Communications (-5.6%), Sylvamo (-8%), and Goldman Sachs BDC (income -8.5% QoQ). Margin compression affected 12/25 companies (avg -200bps, e.g., AdvanSix 1.2% vs 13.7%, Ziff Davis EBITDA -11.2%), driven by higher costs, weather, and one-offs, while capital returns strengthened with $1.4B+ in buybacks (e.g., Republic $317M, Vistra $372M, Yum China $218M) and steady dividends (e.g., Kodiak $0.49, Princeton flat $0.12). M&A activity surged with 5 deals/LOIs (TOMI $120M EV merger, RE/MAX merger, Two Harbors cash up to $12/share, TDS Array proposal), signaling consolidation; biotech/healthcare highlighted pipeline catalysts (Artiva Phase 3 H2 2026). Institutional 13Fs showed concentrated bets on tech/semiconductors (e.g., Act Two MSFT/AAPL, Central Asset semis). Implications: Favor growth sectors like energy/tech/staffing for portfolios, monitor margin pressures and Q2 guidance for cyclicals.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 08, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary stream (including adjacent sectors like tech, gaming, and REITs), Q1 2026 results show mixed performance with 12/20 quarterly reporters posting YoY revenue growth averaging +17% (led by Cloudflare +33.5%, Fortinet +20.1%, DraftKings +17%, Array Digital +93%), but 8 experiencing declines averaging -6% (Ultralife -6.5%, Ziff Davis -1.9%, Fluor -8%). Margin compression is prevalent in 10/15 cases (avg -100bps), offset by strong capital returns including $2.5B+ in buybacks (Fortinet $823M, Yum China $218M, Topgolf $42M) and steady dividends (Strawberry Fields REIT $0.17/share). Divestitures generated $2B+ in gains/cash (Fluor NuScale $1.4B, Array spectrum $1B+), boosting liquidity amid operating losses in 9/20 firms. Forward guidance mixed: raised by Interface (+2% FY sales), deferred by Ziff Davis, reaffirmed by DraftKings/Enbridge. IPO activity (Applied Aerospace, Fervo Energy) signals growth optimism, while Nasdaq compliance risks (Profusa) and litigation hits (Burford -$1.6B) highlight volatility. Portfolio-level trend: digital/gaming outperforming traditional retail/manufacturing, with buybacks signaling management conviction despite macro pressures.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 08, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (though heavily featuring financials, REITs, and 13Fs with limited pure healthcare plays), Q1 2026 period-over-period trends reveal robust revenue growth averaging +15-20% YoY in reporting firms like AbbVie (+12.4%), CoreWeave (+111.6%), Paylocity (+10.5%), and banks (e.g., Peapack-Gladstone NII +32%), but net income volatility with 6/12 mixed earners showing compressions (e.g., AbbVie NI -46%, Citizens & Northern -96%) due to higher provisions, R&D, and expenses. Healthcare highlights include Cellectar Biosciences' $35M raise for Phase 3 trial amid strong Phase 2b data (83.6% ORR), Edwards Lifesciences' strong AGM support (>88%), and AbbVie's revenue beat offset by IPR&D costs. Capital allocation trends favor dividends (CBL +39% to $0.625/share, NewLake 90% AFFO payout) and buybacks (News Corp $456M YTD), with 13Fs signaling institutional conviction in tech (NVIDIA, Apple top holdings across 20+ filers). Portfolio-level patterns show margin pressures in high-growth (avg -100bps implied) vs. stability in banks; actionable now: pivot to funded biotechs and dividend hikes amid mixed guidance.

18 high priority 32 medium 50 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 07, 2026

Across 50 SEC filings from NASDAQ-100 constituents for Q1 2026 (filed May 7), results reveal mixed performance with 12/22 earnings reports showing revenue declines averaging -4.2% YoY (e.g., Optimum -4%, Maximus -4%, MSG +2% outlier), offset by margin expansions in 8/22 cases (avg +90 bps, led by Warner Music +250 bps to 22.9%). Biotech and pharma firms (Evommune, ImmunityBio, Acadia, Gilead) highlight pipeline catalysts amid wider losses, while media/entertainment (Warner +17% revenue, MSG +2%) outperforms on streaming/concerts. Capital allocation trends positive with dividend hikes (Murphy, Saga $0.25, Chemung $0.34), buybacks (Maximus $400M refresh, Radian $50M, Gilead $419M), and 5 debt issuances/refinancings (Booking $750M, ADP $1B). Financials/banks show EPS surges (Camden +199% to $1.29, Chemung +53% to $1.91) despite asset flatness. Portfolio-level: 14/50 mixed sentiment, impairments drag telecom (Optimum $2.7B hit), but guidance raises (Maximus EBITDA +20bps to 14.2%, EPS +$0.20) and catalysts build alpha potential. Implications: Favor media/biotech turnarounds, monitor telecom leverage (Optimum 7.5x), rotate from laggards amid capex cuts (Optimum -13.6%).

24 high priority 26 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 07, 2026

Across the 50 pre-analyzed SEC filings from the USA S&P 500 Financials stream (though spanning diverse sectors including pharma, retail, energy, and tech), Q1 2026 results reveal resilient revenue growth averaging +25% YoY in 28/50 companies (e.g., Celsius +138%, Ormat +76%, Loar +36%), driven by acquisitions, volume ramps, and pricing, but offset by widespread margin compression (-200 to -400 bps in 15 cases like Celsius, GigaCloud) and cost inflation (SG&A up 9-25% in multiple filers). Profitability is mixed with net income rising in 18 cases (e.g., Targa +77%) but declining sharply in 20 (e.g., Bob's -81%, Kelly -op loss widening), amid active capital allocation via buybacks ($24M Celsius, $55M Targa, $17M Consensus) and dividends (Targa +25% YoY, BXSL 11.7% yield). M&A/divestitures dominate (Centessa-Lilly $38/share + CVR, Kontoor Lee divestiture, Spectrum Oaktree $127M), with 12 guidance raises (e.g., Targa EBITDA to $5.7-5.9B) signaling confidence, while 3 withdrawals (Leggett) flag uncertainty. Portfolio-level trends show improving free cash flow in 10 cases but cash burn/inventory builds in 12, implying selective opportunities in high-growth outperformers amid sector headwinds. Financials subset (BXSL, Aflac, WhiteHorse, FHLB Chicago) highlights stable dividends despite NII softness, underscoring defensive positioning.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 07, 2026

Across 50 SEC filings dated May 7, 2026, primarily Q1 FY2026 results for diverse firms (despite Consumer Staples labeling, spanning consumer brands, biotech, energy, finance), revenue trends are mixed with standout growth in branded consumer plays (Celsius +138% YoY to $782.6M, Kontoor Brands +45% to $613M continuing ops, Tapestry +21% to $1.92B) contrasting declines (Aspen Aerogels -52% to $37.9M, Krispy Kreme -2.2% to $367M, Rockwell Medical -8% to $17.3M). Margin expansions prevalent in 7/15 detailed reporters (ARKO fuel +20.1% to 48c/gal, Krispy Kreme EBITDA +380bps to 9%, Callaway gross +250-260bps), but compressions hit growth firms (Claritev EBITDA margin -140bps to 60%, Celsius gross -400bps to 48.3%). Guidance largely raised or steady (Kontoor FY rev $3.41-3.46B up, Callaway sales $2.015-2.07B raised $35-70M, Tapestry ~$7.95B +14%; ARKO unchanged $245-265M EBITDA), signaling management conviction amid YoY improvements in net losses (ARKO -56% narrower, Climb Bio -34%). Capital allocation aggressive with buybacks (Kontoor $750M new auth, GigaCloud $12.3M Q1/$68M remain, Callaway 5.6M shares), dividends (ARKO $0.03/sh, Dorian LPG irregular $1.00/sh), and debt reduction (ARKO $206M via IPO). Biotech pipeline catalysts dense (Climb Bio Fast Track/FDA orphan, Monte Rosa Phase 2 H2 2026), while cash flows deteriorated in 6/12 (GigaCloud op cash $(21.7)M vs +$9.4M YoY, Claritev FCF $(92.5)M worse). Portfolio-level: 14/22 Q1 reporters avg +28% rev growth but -15% avg op cash YoY; mixed sentiment (18/22 mixed) implies selective opportunities in margin outperformers and guidance raisers.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 07, 2026

Across 50 SEC filings from S&P 500 Industrials and related sectors (May 7, 2026), Q1 2026 results dominate with mixed sentiment (24/37 detailed filings mixed), showing average revenue growth of ~25% YoY in biopharma/services (e.g., BridgeBio +67%, Codexis +102%, Pattern Group +43%) but persistent net losses widening in 12/20 cases amid rising opex/SG&A. Industrials-specific trends include sharp declines (Aspen Aerogels rev -52% YoY) offset by infrastructure plays like Target Hospitality's AI/data center board addition. Capital allocation leans shareholder-friendly with buybacks/repurchases in 8 filings (e.g., BridgeBio $500M, First Advantage $100M auth, Abacus $20M add'l), dividends steady (VAALCO $0.0625/share), and debt management (Ocugen repaid loan). Guidance mostly reaffirmed/raised (7/10 cases, e.g., Ligand royalty $225-250M up prior), signaling conviction despite cash burn; forward catalysts cluster Q2-Q3 (earnings, M&A closes, FDA nods). Portfolio-level: 15/50 show cash strengthens (avg +30% QoQ), but 10 flag risks like going concerns (Unity Forge), auditor resigns (Quest Water). Implications: Favor growth names with raised guidance/buybacks for near-term alpha, monitor industrials for capex/revenue recovery amid regulatory drags.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 07, 2026

Across 29 filings in the USA S&P 500 Energy stream, energy firms like Cheniere entities and Targa Resources dominate with mixed Q1 2026 results: revenues grew 8-63% YoY in LNG operations but cost of sales surged 100-240% YoY, driving massive net losses (e.g., Cheniere $3.5B loss vs $353M income) due to $4.8B non-cash derivative hits, offset by strong Adjusted EBITDA (+13-25% YoY) and raised FY2026 guidance. Midstream peers Targa and Hess showed resilience with EBITDA/NI gains (Targa +19%/+77% YoY) and Permian volume records, while upstream Chevron (-37% NI) and APA (+28.5% NI despite -11.7% rev) reflect commodity price pressures. Capital returns accelerated with Targa's 25% div hike ($1.25/share), Cheniere distributions ($0.79/unit), and widespread buybacks ($542M Cheniere, $55M Targa). Non-energy noise (e.g., Papa Johns -7.7% rev, Xometry +36% rev) dilutes but highlights broader market cost inflation; 13Fs signal institutional interest in energy (e.g., Chesapeake's Conoco/Occidental/SLB positions). Portfolio trend: 6/9 energy cos with rev growth but margin compression averaging -500bps+ from costs, bullish EBITDA signals shareholder returns amid volatility. Key implication: Favor midstream over LNG/upstream for near-term stability, watch Q2 catalysts like Cheniere Train 6.

16 high priority 13 medium 29 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 07, 2026

Across the 50 SEC filings from Dow Jones 30-related streams, dominant themes include robust M&A and SPAC activity in nuclear/energy (Hennessy/ONE Nuclear, General Fusion, Catalyst Pharma acquisition), explosive revenue growth in consumer products (Celsius +138% YoY, Kontoor +45% YoY), and biotech pipeline advancements amid cash burns (Vera PDUFA July 2026, Evommune Phase 2b readouts). Period-over-period trends show 18/25 detailed filers with YoY revenue growth averaging +35% (range -4% to +167%), but margins mixed with 9 expansions (avg +200 bps, e.g., MasterCraft +420 bps) vs 7 compressions (avg -150 bps, e.g., Celsius -400 bps); EBITDA improvements in 14 cases (avg +50%). Critical developments: 5 M&A/mergers (e.g., Catalyst $4.1B at 21-28% premium, MasterCraft vote May 12), 4 guidance raises (Kontoor revenue to $3.41-3.46B, AvePoint ARR $523-529M), and equity/debt raises ($405M Avalo, $750M Booking notes). Portfolio-level patterns flag sector rotation opportunities in consumer/energy (+100%+ growth outliers) vs telecom/utilities caution (Optimum -4% rev, impairments), with capital returns via buybacks ($750M Kontoor, $24M Celsius) signaling conviction amid mixed sentiment (14/25 mixed, 6 positive). Implications: Bullish for acquisitive consumer/biotech names, monitor nuclear catalysts for DJ30 energy proxies.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 07, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent sectors), Q1 2026 showed robust revenue growth averaging 15-25% YoY in 12/20 detailed reporters (e.g., Marcus & Millichap +18.2%, LifeStance +21%, SoFi +42%), but pervasive margin compression (-100 to -200 bps in 6/12 cases like Marine Products -200 bps) and mixed profitability with 7/20 posting losses or declines. Capital allocation remains shareholder-friendly, with $150M+ in buybacks (Marcus $23.5M, First Advantage $33.3M total) and dividends declared (RGA $0.93, BXSL $0.77 Q2). Forward guidance mostly stable or raised (LifeStance revenue to $1.64-1.68B FY, Oportun EPS $1.50-1.65), but commodity/crypto funds (15+ filings) exhibited extreme volatility with AUM surges (Invesco DB Energy +111% QoQ) offset by unrealized losses. Insider patterns limited but positive (Target Hospitality AI/data center expert appointment); M&A advances (Marine Products merger Q2 close). Portfolio implication: Favor growth names with buybacks amid margin pressures; monitor commodity exposure for volatility.

41 high priority 9 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 07, 2026

Q1 2026 filings reveal mixed performance across predominantly financials and select S&P 500 Healthcare biotechs/pharma/devices, with financial institutions driving net income growth averaging 35% YoY (e.g., Citizens +36%, Ponce +45%, Kearny +53%, Chemung +53%, Regions +14%, Velocity +18%) on NII expansion (+17% avg YoY) despite some asset contractions and rising provisions. Healthcare biotechs (MindMed, Generate, NewAmsterdam, Edgewise, Harmony) show widened net losses (avg +50% YoY) from R&D ramps (+30-100% YoY) but robust cash positions ($373-707M, runway to 2028) and clustered Phase 2/3 catalysts in 2Q-Q4 2026. Devices/pharma like BD (new CFO), Zoetis (flat org revenue but raised FY guidance 2-5%, Neogen M&A H2), Harmony (+17% WAKIX revenue) signal resilience amid US softness. Capital allocation favors steady dividends (e.g., Ares $0.15 flat) and buybacks (CoreCivic $55M, CION $9.7M shares). 13F-HRs highlight institutional conviction in healthcare (Lilly, JNJ, AbbVie, Merck) within mega-cap heavy portfolios. Portfolio trends: 70% mixed sentiment, revenue +10% avg YoY but op ex +20% avg, provisioning up in CRE/financials; key implication - watch H2 catalysts for healthcare alpha amid financials' deposit/loan stabilization.

19 high priority 31 medium 50 total filings